Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research, Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women's Health Research
and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, California

Lisa A. Carey, MD
The Richardson and Marilyn Jacobs Preyer
Distinguished Professor in Breast Cancer Research
Medical Director, UNC Breast Center
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Kathy S. Albain, MD
Professor of Medicine
Division of Hematology/Oncology
Cardinal Bernardin Cancer Center
Loyola University Health Center
Maywood, IL

Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Matthew G. Ewend, MD
Professor and Chair
Department of Neurosurgery
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Julie R. Gralow, MD
Director, Breast Medical Oncology
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, WA
Vice-Chair, Southwest Oncology Group Breast Committee

Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
Professor, Department of Medicine
Weill Cornell Medical College
New York, NY

Monica Morrow, MD
Chief, Breast Service
Department of Surgery
Anne Burnett Windfohr Chair of Clinical Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY

Hyman B. Muss, MD
Professor of Medicine and Oncology
Director, Geriatric Oncology Program
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

C. Kent Osborne, MD
Director, Breast Center at Baylor College of Medicine
Director, Baylor Cancer Center
Professor of Medicine and Cellular and Structural Biology
Baylor Cancer Center
Houston, TX

Mark Pegram, MD
Director, Breast Cancer Oncology Program
Co-Leader, Molecular Therapeutics Program
Professor of Medicine and Oncology
Stanford University Cancer Institute
Stanford, CA

Edith A. Perez, MD
Group Vice Chair, Alliance for Clinical Trials in Oncology
Deputy Director,
Mayo Clinic Cancer Center
Serene M. and Frances C. Durling Professor of Medicine
Division of Hematology/Oncology
Mayo Clinic
Jacksonville, FL

Andrea L. Richardson, MD, PhD
Assistant Professor
Department of Pathology
Harvard Medical School
Active Staff and Associate Physician
Surgical Pathology
Brigham And Women's Hospital
Boston, MA

Hope Rugo, MD
Professor of Medicine
Department of Hematology/Oncology
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Eric P. Winer, MD
Director, Breast Oncology Center
Thompson Senior Investigator in Breast Cancer Research
Department of Medical Oncology
Professor of Medicine Harvard Medical School
Dana-Farber Cancer Institute
Harvard Cancer Center
Boston, MA

The following measures are used to prevent and monitor for COIs:

1. Learners are always asked in all post-CME/CE activity evaluation forms whether there was any commercial bias, and if so, to explain.
2. For all live courses, the BMLI take two additional measures to help ensure that the learners are made aware of full disclosure prior to all courses:
1. BMLI sends to all pre-registered learners, one week before the live course, an Email containing the complete disclosure of reported conflicts of interest to date and indicating that any conflicts have been resolved.
2. On site at the live course, the BMLI staff members at the registration table personally hand to all learners a copy of the complete and final COI form on a red-colored paper (red color is used for emphasis), and requests that the learner please read the COI form before the activity begins.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI. Please refer to the official FDA prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Sincere appreciation is extended to the following companies for their generous commercial support of this educational meeting: